TSOI lung strategies

This forum is to discuss general things concerning TSOI.
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

TSOI lung strategies

Post by trader32176 »

TSOI lung strategies

OK guys and gals you should ask questions on TSOI lung strategies . It's time to remember them all .
I will try to list them but i might need help from my friends here :

JadiCells for ARDS / Lung pathologies :


Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease

Clinical Stage Immunotherapy Company Aims to Initiate Phase III Clinical Trial to Register Life-Saving Universal Donor Lung Protecting Therapy

https://www.prnewswire.com/news-release ... 25932.html

" We are extremely confident in our ability to take these cells to the finish line in treatment of end stage lung disease."



StemVacs :


Therapeutic Solutions International Reports Regression of Glioma, Lung Cancer and Colorectal Cancer using StemVacs in Animal Models

Published: Jan 25, 2021


https://www.biospace.com/article/releas ... al-models/


OCEANSIDE, Calif., Jan. 25, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today expansion of its preclinical dataset on StemVacs, an umbilical cord generated dendritic cell immunotherapy. In a series of laboratory experiments, StemVacs administration was demonstrated to induce regression of GL261 glioma, CT-26 colorectal cancer, and Lewis Lung Carcinoma tumors grown in mice.

Last week the Company reported that StemVacs administration effectively reduces breast cancer through immune stimulation in a natural killer cell dependent manner1. Mechanistically, regression in glioma, colorectal and lung cancer was also dependent on mice possessing a functional natural killer cells repertoire.

"There are companies developing "off the shelf" natural killer based immunotherapeutics for cancer such as Fate Therapeutics (Market Cap $8.9 Billion) and NantKwest (Market Cap 1.8 Billion)" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "To our knowledge we are the only group working at developing a cellular drug using dendritic cells, which are upstream of natural killer cells during immune activation."

Dendritic cells are usually utilized in an autologous manner, meaning they are generated from the same person that they are used upon. Technologies developed by Therapeutic Solutions International allow for the manufacture of unique dendritic cells from cord blood stem cells, which can be used in a universal donor manner.

"The consistency, reproducibility, and ease of scalability is an attractive feature of StemVacs as a "cellular drug" stated Famela Ramos Vice President of Business Development. "We are seeing more and more acceptance of cellular immunotherapies in the market ranging from the $11 Billion acquisition of Kite by Gilead2, to the enormous public and private valuations for cell therapy companies in early phases of clinical development. Given that we have already treated patients with StemVacs, and we have filed an Investigational New Drug (IND) application for this product, we are excited in its development prospects."

Cord Blood Immunotherapy :


San Diego "Top Doctor" James Veltmeyer Collaborates With Therapeutic Solutions International in Cord Blood Based Immunotherapy for COVID-19 Damaged Lungs

New Findings in Biology of Coronavirus Leads to New Data and the Possibility of Reducing Ventilator Associated Mortality

https://www.prnewswire.com/news-release ... 57622.html

StemVacs V


Therapeutic Solutions International Creates Hybrid Cell Designed to Educate Immune System to Choke Cancer Blood Vessels

Novel Strategy Demonstrates Potent Results in Animal Model of Lung Cancer through Fusing StemVacs-V™ Immunotherapy with In-Vitro Generated Cancer Blood Vessels

https://www.prnewswire.com/news-release ... 53715.html


QuadraMune :

https://microcapdaily.com/the-exciting- ... oi/126685/

TSOI got another boost after the Company reported it has filed a new patent application with the USPTO covering the use of QuadraMune and type 2 diabetes med metformin to treat coronavirus COVID-19 associated lung damage.


NanoStilbene :

https://www.globenewswire.com/news-rele ... lbene.html


Pterostilbene is a naturally occurring analog of resveratrol, which has been published in the peer-reviewed literature to suppress the growth of various types of cancers1 including cervical cancer2, lung cancer3, triple negative breast cancer4, prostate cancer5, and glioma6.

"I am extremely pleased with the promising initial data we are receiving demonstrating efficacy of the NanoStilbene formulation to deliver enhanced concentrations of pterostilbene to the patient's blood stream," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Given the ability of pterostilbene to enhance the efficacy of chemotherapeutic drugs7, as well as having activity as a monotherapy in animal models, we are hoping to expand the use of this highly interesting molecule."
curncman
Posts: 1017
Joined: Fri Jun 26, 2020 8:27 am

Re: TSOI lung strategies

Post by curncman »

Trader , FDA is going to revoke approval on keytruda .. very interesting to see if TSOI can overtake the BIG pharma with fda approval for jadicells and or STEMVACS...


Is Merck Stock A Sell After Panel Suggests Revoking A Keytruda Approval?

Merck stock remains under pressure after an independent panel recommended the Food and Drug Administration revoke an approval for cancer drug Keytruda.

Merck (MRK) drug Keytruda gained approval as a third option in stomach cancer. But the approval was contingent upon additional testing. Further studies didn't confirm the drug's benefit. In late April, an independent panel suggested the FDA revoke Keytruda's approval for that use. The FDA doesn't have to follow the recommendation, but it usually does.

The panel suggested retaining approvals for Keytruda in types of bladder and liver cancer. Bristol Myers Squibb's (BMY) Opdivo lost out in liver cancer, but the panel suggested maintaining Roche's (RHHBY) Tecentriq in forms of breast and bladder cancer.
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: TSOI lung strategies

Post by trader32176 »

yes curncman,

interesting times :) :) :D :D :mrgreen: :mrgreen:

Lung Companies and Organizations

https://www.biotech-careers.org/company ... ivity/lung

Top Respiratory Companies

https://www.ventureradar.com/keyword/Respiratory

Top 22 Lung Cancer Startups

5/11/21


https://www.medicalstartups.org/top/lungcancer/
ken.p
Posts: 12
Joined: Sat Jul 11, 2020 8:39 pm

Re: TSOI lung strategies

Post by ken.p »

Good morning. I was talking with a friend over the weekend and he mentioned something I completely forgot about. Before covid, early 2019, there was an outbreak involving vaping that they named EVALI. It has similar covid symptoms and causes lasting lung damage & breathing difficulties. I immediately thought of TSOI and Jadicells, could this help those patients too?

Recent article: https://www.tandfonline.com/doi/full/10 ... 21.1929927
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: TSOI lung strategies

Post by trader32176 »

ken.p ,

It's a tough call to see certain situations upcoming , and not be able to comment on them -Why ? - because i don't know like everyone else .

TSOI is forging the way toward lung tissue repair. -imho

There are several questions @ the forefront:


Some questions that you might have are about issues in the tissues after vaping ?

How many years of vaping ?

Vaping and pterostilbene ?

Vaping and Stem Cell Repair ?

This company is studying the lungs a lot .

follow to see what they expand into.

GL2U in all of your endeavors !

-Trader
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: TSOI lung strategies

Post by trader32176 »

ken. p,

One more item on vaping :
(DD on the edge - and i have no opinion , and it's not presented here to be spam)

“Pure Anti-Aging” will renew the user’s appearance with two of the most eminent nutraceuticals in the anti-aging community, resveratrol and pterostilbene.

Tuesday, May 25, 2021
RSS Email Newsletters Put PRWeb on your site
After Successful Crowdfunding Campaign Surpassing $90,000, Presales of Vitamin Inhalation Device Sparq Continue on Indiegogo InDemand

https://www.prweb.com/releases/after_su ... 962521.htm
trader32176
Posts: 2696
Joined: Fri Jun 26, 2020 5:22 am

Re: TSOI lung strategies

Post by trader32176 »

Therapeutic Solutions International Develops Novel Stem Cell Based Therapy to Reduce Lung Scarring: Potential Solution to Post COVID-19 Lung Deterioration

https://www.prnewswire.com/news-release ... 96796.html


ELK CITY, Idaho, May 21, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data and patent filing demonstrating that the FDA cleared drug, lithium carbonate, substantially augments the scar inhibiting activity of its licensed JadiCell™ universal donor stem cell therapy. Furthermore, the data reveals that the JadiCell™ was superior to other stem cells at inhibiting development of lung scarring in the bleomycin model of pulmonary fibrosis.

"After patients recover from COVID-19 approximately one-third of those who were hospitalized develop long-term scarring of the lung,1" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "There are no known treatments for this condition, and in some cases its progression leads to continuous deterioration in lung function. We are currently developing the JadiCell™ for treatment of acute lung failure. The data disclosed today suggests the possibility of expanding the use of JadiCell™ to address post-COVID lung failure, a condition which appears to be rising exponentially."

The use of JadiCells for treatment of lung pathology and COVID-19 is exclusively licensed and owned by Therapeutic Solutions International. In an FDA double blind, placebo controlled clinical trial the JadiCell™ was successful at substantially improving survival in end-stage patients with COVID-19 associated acute lung failure2. Specifically, treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), Serious Adverse Event-free survival (P = .008), and time to recovery (P = .03). The Company plans to initiate a phase III pivotal registration trial and seek marketing approval for use of JadiCell in acute respiratory distress syndrome (ARDS) and other lung diseases.

"There are at least 660,000 patients suffering from post-COVID lung fibrosis if you look at the CDC statistics reporting over 2,000,000 COVID-19 related hospitalizations,3" stated Famela Ramos, Vice President of Business Development for the Company. "To our knowledge Therapeutic Solutions International is the only Clinical Stage Cell Therapy company aggressively addressing not only the acute lung failure associated with COVID-19, but also its long-term consequences."

"The findings reported today are an excellent example of the cross-fertilization occurring between our Company and our Spin-off Campbell Neurosciences," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Who would have thought that a neurological acting drug, lithium carbonate, which is sold under the names Lithobid® and Eskalith®, would have such potent ability to program stem cells to reduce scarring? These sorts of discoveries are only possible when scientific groups of diverse interest are brought together and provided resources to let their imagination run rampant."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection (nih.gov)
2 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial - Lanzoni - 2021 - STEM CELLS Translational Medicine - Wiley Online Library
3 COVID Data Tracker Weekly Review | CDC
User avatar
TimGDixon
Posts: 1189
Joined: Fri Jun 26, 2020 4:36 am

Re: TSOI lung strategies

Post by TimGDixon »

Fabulous Famela said "There are at least 660,000 patients suffering from post-COVID lung fibrosis if you look at the CDC statistics reporting over 2,000,000 COVID-19 related hospitalizations"

This is of significant interest to us and whether we combine LC or not, we know full well the regenerative potential of jadi's to repair these lungs. 660,000 patients would have a potential worth of $13,000,000,000 - yeah 13 billy....

There are 16,000,000 Americans with COPD and 65 million world wide. 1/10th of the USA population or 1.6mm would be worth something in the neighborhood of $32,000,000,000 - yeah 32 billy...

But while we wait on the FDA we'll continue to make new discoveries and when applicable file the necessary patent protection... this is pretty much what i'm thinking about this sunday afternoon and not sweating a single thing...

This is for all those pajama boi's out there...

curncman
Posts: 1017
Joined: Fri Jun 26, 2020 8:27 am

Re: TSOI lung strategies

Post by curncman »

Wow that’s 15billy + 32 billy = 47 billy is the target market size in US alone and if you take into account world wide lung repair and may be include Lung Cancer in scope that well over 200billy. It’s an astronomical figure from where we are now just like how Microsoft / Amazon /Pfizer were 30 years ago
Last edited by curncman on Sun Jun 06, 2021 4:46 pm, edited 1 time in total.
User avatar
TimGDixon
Posts: 1189
Joined: Fri Jun 26, 2020 4:36 am

Re: TSOI lung strategies

Post by TimGDixon »

Its a whole lot of billy for sure Curncman...the foreign market that could travel here and pay cash is as big or bigger than the USA population. I think the US Govt. should cover the costs for all lung injured covid-19 victims - they already are with no end game, steroids, nebulizers... that doesn't fix a damn thing and potentially exacerbates the injury over time - steroids long term are never good idea - so its bigger than any of us really realize and i'm sitting smack dab on top of it - so let's see what happens but my sense is we become too big of a threat to those other pharma giants when i can produce all the cells neccessary to treat all those patients while sitting on your river in idaho... its just some contracts with some labs to make, validate, and cryofreeze batches of cells - doctor smith orders 2 vials and we have the lab drop ship directly to doc - doesn't take Pfizer to do that - it takes us. He who holds the goose catches the eggs.... but i have to wrestle with the sheer temptation of an early licensing deal worth mega billy - if you can't write such checks, go away... we'll just churn the rev's ourselves...
Post Reply